

A Rarely Seen Hepatic Tumor: Epithelioid Hemangioendothelioma

Erdinç Nayır

Department of Medical Oncology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey

Abstract

Introduction: Epithelioid Hemangioendothelioma (EHE) is a rarely seen tumor most frequently originating from vascular structures of different regions including liver, followed by stomach, spleen, lung, bone, soft tissue, and skin.

Case Presentation: In this paper, a patient with multiple mass lesions in the liver with a diagnosis of EHE who underwent liver transplantation is presented.

Conclusion: It has an intermediate degree of malignancy between benign hemangioma, and malignant hemangiosarcoma. It can manifest with nonspecific symptoms or hepatic failure. Generally it is seen as a diffuse hepatic disease. The most optimal treatment alternatives are liver resection, and transplantation.

Keywords: Hemangioendothelioma, liver transplantation, liver tumor

Introduction

A 35-year-old male patient consulted to us in January 2015 with complaints of abdominal pain, and lassitude. His physical examination revealed subicteric scleras, and on deep abdominal palpation tenderness at the right upper quadrant was detected. Rebound tenderness, and abdominal guarding were not detected. Presence of abdominal pain, and right upper abdominal quadrant tenderness on palpation required abdominopelvic ultrasonographic (US) examination. On US, hypo-echoic solid lesions on hepatic segments 2 (8.5 mm), and 7 (12x10 mm) were observed.

His hemogram, and biochemical examinations did not reveal any abnormality. For better identification of the hepatic lesion upper abdominal dynamic magnetic resonance (MR) images were obtained. On MR multiple T₂ hyperintense, and T₁ hypointense nodules in the liver parenchyma, the biggest one measuring 18x16 mm at segment 7 were detected. On dynamic phase series, peripheral diffuse contrast uptake was seen, and wash-out was not observed in late-phase series. In some of these lesions non-stained areas possibly consistent predominantly with central necrosis were noted (Figure-1). Radiologist

Corresponding Author: Erdinc Nayir, MD; Kahramanmaras Necip Fazil City Hospital, 46050, Kahramanmaras, Turkey
E-mail: drerdincnyr@gmail.com

Received: Jan 8, 2016 **Accepted:** Feb 21, 2016
Published: March 30, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction in any area, provided original work is properly cited.

The Ulutas Medical Journal © 2014



interpreted the MR images in favour of metastasis. Because of suspect hepatic metastasis, measurement of hepatitis biomarkers, AFP, CA 19-9, and CEA levels were requested. Biomarkers of hepatitis, and tumor were within normal limits. Chest X-ray, thoracic computed tomography (CT), scrotal US, endoscopic, and colonoscopic examinations were requested from the patient in order to search for the primary focus. On scrotal US of the patient whose chest X-Ray, and thoracic CT were unremarkable, slightly varicose veins of 3.5 mm in their largest diameter were detected. Grade-A esophagitis was detected on his endoscopic examination, while his colonoscopy did not reveal any abnormality.




Figure-1. MR images of mass lesions in the liver on T₂ weighted sequence

On positron emission tomograms (PET-CT) obtained so as to detect the primary focus, increased FDG uptake suggesting malignancy was detected on the left supraclavicular (SUV_{max}:4.4), left inferior jugular (SUV_{max}: 4.6), and in the mediastinum prevasküler (SUV_{max}: 3.9), right inferior paratracheal (SUV_{max}: 4.9), left inferior paratracheal (SUV_{max}:4), right hilar

(SUV_{max}:3.5), left hilar (SUV_{max}: 5.4) and subcarinal (SUV_{max}: 5.7) lymph nodes (SUV_{max}: 5.7, metastasis)(Figure-2).




Figure-2. PET-CT image of the patient

The liver lesions of the patient were biopsied under the guidance of US. Immunohistochemical examination of the biopsy material disclosed CD34, and vimentin positivity, while pancytokeratine, hepatocyte, CEA, CK7, CK20, TTF-1, CDX-2, S-100, DOG-1, and actin negativity. As a result of immunohistochemical staining the diagnosis of the patient was reported as epithelioid hemangioendothelioma.

The patient with multiple mass lesions who was diagnosed as epithelioid hemangioendothelioma underwent liver transplantation from a live donor in June 2015. Posttransplantation follow-up period of the patient is uneventful.

Discussion

Epithelioid hemangioendothelioma is a rarely seen tumor originating from vascular structure of different regions including stomach, spleen, liver, lungs, bone, soft tissue, and skin. It has an intermediate degree of malignancy between benign hemangioma, and malignant hemangiosarcoma (4). Most frequently liver is involved (5). In our patient also hepatic involvement was detected.

The patients most frequently present with symptoms, and signs of abdominal pain, weight loss, ascites, nausea, jaundice, hepatic failure, hepatic vein thrombosis, and portal hypertension (6). In our patient, abdominal pain, and jaundice were detected. Imaging modalities is very important in the diagnosis of EHE. On ultrasonographic examination it is frequently (66.3%) seen as a hypoechoic, and occasionally (22.5%) as a heterogeneous lesion. On non-contrasted CT, they are seen as hypodense, non-homogeneous solid nodules extending into the capsule frequently with a peripheral location. After injection of the contrast material a halo sign formed by a central scar, and a peripheral cell proliferation at the portal venous phase become manifest. On MR, they are seen as non-homogeneous hypointense at T₁, and non-homogeneous hyperintense images at T₂ sequences (7). On MR of our patient multiple number of nodular lesions in the parenchymal tissue the biggest one with the dimensions of 18x16 mm were observed. These nodules were visualized as

hypertense lesions at T₂, and hypotense lesions at T₁ sequences together with peripheral diffuse contrast uptake in dynamic phase sequences.

For definitive diagnosis histopathological examination is required. On microscopic examination it is very difficult to differentiate these lesions from cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, sarcoma, and metastatic tumors. Definitive diagnosis can be made by confirmation of endothelial cells using immunohistochemical methods (factor VIII, CD34, and CD31 tracers). Presence of increased levels of endothelial cell markers in dendritic and/or epithelioid cells confirms diagnosis (8). Immunohistochemical analysis performed in our patient disclosed CD34, and vimentin positivity.

As a treatment, various methods can be tried based on the location of the tumor in the liver. Among these methods, liver resection, and transplantation are the predominant treatment modalities (9). In EHE cases with diffuse, and unresectable hepatic involvement, even in the presence of distant metastases, liver transplantation is the most suitable treatment modality. (10, 11, 12). Also in our case, due to diffuse hepatic involvement, as a treatment modality liver transplantation was preferred.

In the study where 71 patients did not undergo any treatment, while other patients were treated with liver transplantation (n:128), chemotherapy and/or radiotherapy (n:60), and hepatic resection (n:27). In this study, 1-year and 5-year survival rates following liver transplantation were reported as 96, and 54.5%, while in the groups of chemotherapy radiotherapy, and liver resection, corresponding 1-year and 5-year-survival

rates were 73.3, and 30%, and 75%, respectively (3).

In conclusion, when multiple liver mass lesions are encountered, EHE should be absolutely considered in the differential diagnosis

Reference

1. Dong K, Whang X, Feng JL et al. Pathological characteristics of liver biopsies in eight patients with hepatic epithelioid hemangioendothelioma. *Int J Clin Exp Pathol* 2015;8(9): 11015-23.
2. Pregliasco AG, Wendum D, Goumard C et al. Hepatic epithelioid hemangioendothelioma. *Clin Res Hepatol Gastroenterol* 2015 Nov 3. pii: S2210-7401(15)00254-5.
3. Mehrabi A, Kashfi A, Fonouni H et al. Primary malignant hepatic epithelioid hemangioendothelioma: A comprehensive review of the literature with emphasis on the surgical therapy. *Cancer* 2006;107:2108-21.
4. Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: A vascular tumor often mistaken for a carcinoma. *Cancer* 1982;50:970-81 .
5. Sangro B, Inaarriraegui M, Fernandez-Ros N. Malignant epithelioid hemangioendothelioma of the liver successfully treated with sorafenib. *Rare Tumors* 2012;4:e34 .
6. Caruso S, Miraglia R, Maruzelli L et al. An unusual presentation of malignant hepatic epithelioid hemangioendothelioma with left pleural and pulmonary localization. *Pediatr Radiol* 2008;38:1027-30
7. Ji ZF, Shen XZ, Zhang DY et al. Hepatic epithelioid hemangioendothelioma: a report of six patients. *J Dig Dis* 2010;11:254-8.
8. Tsuneyoshi M, Dorfman HD, Bauer TW. Epithelioid hemangioendothelioms of bone: a clinicopathologic, ultrastructural, and immunohistochemical study. *Am J Surg Pathol* 1986;10:754-64.
9. Langrehr JM, Petersen I, Pfitzmann R, Lopez-Hanninen E. Malignant epithelioid hemangioendothelioma of the liver. Result of surgical treatment strategies. *Chirurg* 2005;76:1161-7.
10. Lerut JP, Orlando G, Sempoux C et al. Hepatic hemangioendothelioma in adults: Excellent outcome following liver transplantation. *Transpl Int* 2004;17:202-07.
11. Ben-Haim M, Roayaise S, Ye MQ et al. Hepatic epithelioid hemangioendothelioma: Resection or transplantation, which and when? *Liver Transpl Surg* 1999;5:526-31.
12. Lerut JP, Orlando G, Adam R. The place of liver transplantation in the treatment of hepatic epithelioid hemangioendothelioma: report of the European liver transplant registry. *Ann Surg*. 2007 Dec;246(6):949-57.

How to cite?

Nayir E. A Rarely Seen Hepatic Tumor: Epithelioid Hemangioendothelioma. *Ulutas Med J*. 2016;2(1):59-62.

DOI: [dx.doi.org/10.5455/umj.20160121062843](https://doi.org/10.5455/umj.20160121062843)

Why the Ulutas Medical Journal ?

- Convenient online Pdf submission
- **Fast response** through peer review
- No space constraints or color figure charges
- Immediate publication after acceptance
- Inclusion in **Scopemed** and **Google Scholar**

To submit your manuscript, please click on <http://ulutasmedicaljournal.com>